Dr. Chu is a Clinician Investigator and an Assistant Professor in the Department of Radiation Oncology at Sunnybrook and the University of Toronto. He is an active member of the Gastrointestinal and Genitourinary Cancer Care teams.
Dr. Chu is an Affiliate Scientist in Physical Sciences at the Sunnybrook Research Institute. The focus of his research is the development and evaluation of innovative, high-impact radiation treatment strategies to improve patient outcomes and quality of life. He sustains national and international collaborative studies, and his areas of research include:
1) Stereotactic body radiotherapy (SBRT) for patients with kidney and prostate cancer, and tumours involving the liver, pancreas, adrenal glands and lymph nodes. He is the principal investigator of a Canadian multi-centre, phase II study of SBRT for patients with inoperable renal cell carcinoma, a co-investigator of studies combining SBRT with immunotherapy and targeted therapy for patients with metastatic renal cell carcinoma, and the Canadian lead of an international randomized phase III trial of prostate SBRT
2) Early phase studies of MRI-guided radiotherapy and HIFU/hyperthermia for patients with rectal cancer